Shuichi Hironaka

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 548 citations

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Yasuhide Yamada, Katsuhiko Higuchi, Kazuhiro Nishikawa et al. · Annals of Oncology · 2014 · 524 citations · Full text

Chemotherapy-naïve Patients, Gastrointestinal Oncology, Advanced Gastric Cancer +8

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato et al. · The Lancet Oncology · 2017 · 378 citations

Surgical Oncology, Esophageal Cancer, Nivolumab Treatment +8